Plain-English translation of NCT05760612 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a combination of works better than for women with HER2-positive breast cancer. You would have already received chemotherapy and surgery before joining this study. The study wants to see if adding neratinib—a newer type of medication that works differently than pertuzumab—can help prevent the cancer from coming back.
After chemotherapy and surgery, some women still have a small amount of cancer remaining. Doctors want to find the best way to treat these remaining cancer cells to reduce the chance of the cancer returning. This medication is being tested because it may work in a new way that could be more effective than the current standard treatment.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the combination of or . If you receive neratinib, you would take it as a daily pill by mouth. Both groups would receive trastuzumab as an IV infusion every 3 weeks for a total of 18 cycles. Your heart function would be monitored regularly, and you would have follow-up visits to check for side effects and how well the treatment is working.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
China